Shots:

• The P-IIb (SOLANO) study evaluates the efficacy, safety, and tolerability of ION449 (60mg) vs PBO in 411 patients with hyperlipidemia LDL-C ≥70 mg/dL and <190mg/dL on maximum tolerated statin & ezetimibe
• The trial met its 1EPs i.e., the therapy showed a 62.3% reduction in low-density lipoprotein cholesterol (LDL-C) levels @28wks., was safe and well tolerated. Additionally, the therapy will not advance into P-III development, based on the pre-specified efficacy criteria
• The therapy has been developed by using the LICA technology platform that helps to reduce plasma levels of proprotein convertase subtilisin/Kexin type 9 (PCSK9)

Ref: PRNewswire | Image: Ionis